Key regions: Japan, India, Italy, Brazil, South Korea
The demand for Anti-Hypertensive Drugs in Algeria has been increasing steadily over the past few years.
Customer preferences: Algerian customers tend to prefer generic drugs due to their affordability and easy accessibility. This trend is also seen in the Anti-Hypertensive Drugs market where generic drugs are more commonly used than branded ones. Additionally, with the aging population, there is a growing need for effective and affordable drugs to manage hypertension.
Trends in the market: The Anti-Hypertensive Drugs market in Algeria is expected to grow due to the increasing prevalence of hypertension and the government's efforts to improve healthcare facilities. The market is also witnessing a shift towards combination drugs that offer better efficacy and convenience to patients. The availability of these drugs in various dosage forms such as tablets, capsules, and injections has also contributed to the growth of the market.
Local special circumstances: One of the major challenges faced by the Anti-Hypertensive Drugs market in Algeria is the availability of counterfeit drugs. The government has taken several measures to combat this issue, including increasing the penalties for those found guilty of producing or selling counterfeit drugs. Another challenge is the lack of awareness among the general population about hypertension and the importance of managing it.
Underlying macroeconomic factors: Algeria's economy heavily relies on the oil and gas sector, which has been experiencing a decline in recent years. This has resulted in a decrease in government spending on healthcare, which could potentially impact the growth of the Anti-Hypertensive Drugs market. However, the government's focus on improving healthcare infrastructure and increasing access to essential medicines is expected to drive the growth of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
